ID
38479
Beschrijving
Study ID: 108062 Clinical Study ID: 108062 Study Title: A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoietin receptor agonist, in previously treated pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP). Eltrombopag PETIT: Eltrombopag in PEdiatric patients with Thrombocytopenia from ITP Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00908037 https://clinicaltrials.gov/ct2/show/NCT00908037 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: eltrombopag, Placebo Trade Name: N/A Study Indication: Purpura, Thrombocytopaenic, Idiopathic The study consists of a screening, Day 1 and three parts. All subjects were supposed to receive 24 weeks (6 months) of eltrombopag treatment during Part 2/3. Screening period: Up to 28 days prior to Day 1 of treatment. Day 1 Part 1 (Dose Finding Phase): A 24-week (6 months) open label treatment period for 5 subjects in each age cohort. (short: P1W1-P1W7, P1W8-23, P1W24/EW). A safety, PK and platelet count review took place after 12 weeks (3 months) of treatment. Subjects in the Dose Finding Phase did not participate in the Randomized Period. Part 2 (Randomized Period): A 7-week randomized, double-blind, placebo-controlled period involving 18 subjects per cohort (short: P2W1-P2W7). Part 3: An open-label treatment period where subjects randomized to eltrombopag in Part 2 received an additional 17 weeks of eltrombopag in Part 3 and subjects randomized to placebo in Part 2 received 24 weeks of eltrombopag in Part 3 (short: P3W8-P3W23, P3W24/EW, P3W8-30, P3W31/EW). Follow-up: 4 weeks following the last dose of eltrombopag (short: FUW1- FUW4). Additional ocular examinations were performed at 12 and 24 weeks (3 and 6 months) after the last dose of eltrombopag (short: FUM3, FUM6). The subjects were enrolled in 3 cohorts: Cohort 1: Subjects between 12 and 17 years old (<18 years of age at Day 1). Cohort 2: Subjects between 6 and 11 years old (<12 years of age at Day 1). Cohort 3: Subjects between 1 and 5 years old (<6 years of age at Day 1). The enrollment was started with the oldest cohort (Cohort 1). The younger cohorts were not enrolled until safety, PK and platelet counts had been reviewed in the older cohort(s). This document contains the blood products and blood supportive care products and status of treatment blind form. It has to be filled in for Logs and repeats.
Link
https://clinicaltrials.gov/ct2/show/NCT00908037
Trefwoorden
Versies (2)
- 21-10-19 21-10-19 -
- 05-12-19 05-12-19 - Sarah Riepenhausen
Houder van rechten
GlaxoSmithKline
Geüploaded op
21 oktober 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Effects of eltrombopag in children with chronic idiopathic thrombocytopenic purpura, NCT00908037
Logs and repeats: Blood products and blood supportive care products and status of treatment blind
Beschrijving
Blood products and blood supportive care products
Alias
- UMLS CUI-1
- C0456388
- UMLS CUI-2
- C0018938
Beschrijving
In the original form this item is hidden.
Datatype
integer
Alias
- UMLS CUI [1]
- C2348184
Beschrijving
If you tick "Other Blood Product" or "Other Blood Supportive Care Product", please specify in the appropriate items.
Datatype
text
Alias
- UMLS CUI [1]
- C0456388
- UMLS CUI [2]
- C0018938
Beschrijving
Other Blood Product
Datatype
text
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0456388
- UMLS CUI [1,3]
- C2348235
Beschrijving
Other Blood Supportive Care Product
Datatype
text
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0018938
- UMLS CUI [1,3]
- C2348235
Beschrijving
Cumulative Quantity or Dose
Datatype
float
Alias
- UMLS CUI [1]
- C2986497
Beschrijving
Units
Datatype
text
Alias
- UMLS CUI [1,1]
- C1519795
- UMLS CUI [1,2]
- C0456388
- UMLS CUI [2,1]
- C1519795
- UMLS CUI [2,2]
- C0018938
Beschrijving
day month year 00:00-23:59
Datatype
partialDatetime
Alias
- UMLS CUI [1]
- C3897500
Beschrijving
day month year 00:00-23:59
Datatype
partialDatetime
Alias
- UMLS CUI [1]
- C3899266
Beschrijving
Status of treatment blind
Alias
- UMLS CUI-1
- C0749659
- UMLS CUI-2
- C2347038
Beschrijving
If yes, complete the Adverse Event form and/or Investigational Product forms as appropriate. Fill in also date and reason of blind broken in the appropriate items.
Datatype
text
Alias
- UMLS CUI [1]
- C3897431
Beschrijving
day month year
Datatype
date
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C0011008
Beschrijving
Reason blind broken
Datatype
text
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C0392360
Beschrijving
Other reason blind broken, specification
Datatype
text
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C0392360
- UMLS CUI [1,3]
- C3845569
- UMLS CUI [1,4]
- C2348235
Similar models
Logs and repeats: Blood products and blood supportive care products and status of treatment blind
C0018938 (UMLS CUI-2)
C0018938 (UMLS CUI [2])
C0456388 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,3])
C0018938 (UMLS CUI [1,2])
C2348235 (UMLS CUI [1,3])
C0456388 (UMLS CUI [1,2])
C1519795 (UMLS CUI [2,1])
C0018938 (UMLS CUI [2,2])
C2347038 (UMLS CUI-2)
C0011008 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])
C3845569 (UMLS CUI [1,3])
C2348235 (UMLS CUI [1,4])